Shots:

• Biocon Biologics has acquired Pfizer’s 60-000 sq. ft state-of-the-art- bench to pilot scale R&D facility at TICEL Bio Park in Chennai- India
• The focus of the acquisition is to expand Biocon’s R&D capabilities and to accelerate the development of its biosimilars from lab to pilot scale- addressing the needs of patients globally
• The facility will house an early stage R&D center including pilot-scale R&D unit- equipped with cell line development- drug substance process development from bench scale to 400L scale bioreactors- drug product formulation laboratories- analytical R&D laboratories with 250+ scientists

Click here to­ read full press release/ article | Ref: Biocon | Image: Twitter